|
New York
Menlo Park
Washington DC
São Paulo
London
|
Paris
Madrid
Tokyo
Beijing
Hong Kong
|
|
|
|||
Deanna L. Kirkpatrick
|
|||
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, NY 10017
|
212 450 4135 tel
212 701 5135 fax
deanna.kirkpatrick@davispolk.com
|
||
December 20, 2012
|
Confidential Draft Registration Statement on Form S-1
Submitted November 9, 2012
CIK No. 0001561387
|
1.
|
We note that there are a number of additional exhibits that still need to be filed. Please provide these exhibits as promptly as possible. Please note that we may have comments on these materials once they are provided.
|
U.S. Securities and Exchange Commission
|
2
|
December 20, 2012
|
|
The Company acknowledges the Staff’s comment and will file all exhibits in time to give the Staff sufficient time to review the exhibits prior to distribution of the preliminary prospectus.
|
2.
|
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
|
|
The Company confirms that the graphics included in its registration statement are the only graphics that the Company will use in its prospectus.
|
3.
|
Since you appear to qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, please describe how and when you may lose emerging growth status.
|
|
The Company has added disclosure under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—JOBS Act” to describe how and when it may lose emerging growth status.
|
4.
|
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications. Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.
|
|
The Company acknowledges the Staff’s comment and will supplementally provide the Staff with materials that were presented to potential investors in reliance on Section 5(d) of the Securities Act. The Company will also supplementally provide to the Staff any research reports that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 by any broker or dealer that is participating or will participate in the offering.
|
5.
|
You disclose that you intend to list your Class A common stock on the NASDAQ Global Market under the symbol “HIIQ.” Please revise your disclosure throughout your registration statement, including here and page 94, to clarify whether you applied to obtain listing on the NASDAQ Global Market, and if so, the status of your application. If you have not yet filed an application, please expand your disclosure to clearly state that an application has not yet been filed and disclose when you expect to file such an application.
|
|
The Company has revised the disclosure on the cover page and on pages 97 and 104 of the Registration Statement to clearly state that an application to obtain listing on the NASDAQ Global Market has not yet been filed and that the Company expects to file such an application following the filing of the Registration Statement.
|
U.S. Securities and Exchange Commission
|
3
|
December 20, 2012
|
6.
|
Please provide updated financial statements and updated financial disclosures through the period ended September 30, 2012. Refer to Rule 8-08 of Regulation S-X.
|
|
The Company has provided updated financial statements and updated financial disclosures through the period ended September 30, 2012.
|
7.
|
We note the statements in the last paragraph on page ii concerning industry and market data. It is not appropriate to imply that you are not liable for statements included in your registration statement. Please delete these statements or specifically state that you are responsible for the referenced information.
|
|
The Company acknowledges the Staff’s comment and has deleted these statements.
|
8.
|
We note that you refer to yourself as a “leading developer” or as an “industry leader.” Please provide the basis for these characterizations or alternatively, please delete the use of such references throughout your registration statement.
|
|
The Company’s statements regarding its position as a “leading developer” or as an “industry leader” are based on a summary prepared by Re-Solutions Intermediaries, an independent reinsurance intermediary (please find attached as Exhibit A), of short-term medical (“STM”) business in 2011 as reported to the National Association of Insurance Commissioners (“NAIC”). The NAIC is the U.S standard-setting and regulatory support organization created and governed by the chief insurance regulators from the 50 states, the District of Columbia and five U.S. territories. The summary lists approximately 50 STM writers and their respective numbers of STM policies in force as of December 31, 2011. By way of example, the summary provides that the numbers of STM policies in force as of December 31, 2011 of the top 3 carriers as reported to NAIC were as follows:
|
Time Insurance Co.
|
9,668
|
HealthCare Svc Corp.
|
9,036
|
Humana Insurance Co.
|
6,044
|
|
By comparison, the Company had 18,059 STM policies in force as of December 31, 2011, nearly double that of Time Insurance Co, the top reporting carrier. The Company believes that the Re-Solutions Intermediaries report provides sufficient basis for these characterizations.
|
9.
|
Please expand your disclosure to briefly describe your short term medical, or STM, insurance plans and how they differ from traditional Individual Major Medical, or IMM, plans. Similarly, please describe your guaranteed-issue hospital indemnity plans and your other ancillary products.
|
U.S. Securities and Exchange Commission
|
4
|
December 20, 2012
|
10.
|
Please expand your discussion to explain what you mean by the phrase “our sales are executed online and offer instant electronic fulfillment” and discuss whether this service is available only for policies that meet established criteria or all of the products you offer.
|
|
The Company has added disclosure under the headings “Prospectus Summary—Overview—Our Company,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business—Overview—Our Company” to explain the phrase “our sales are executed online and offer instant electronic fulfillment” and to note that this service is available for all products that the Company offers.
|
11.
|
Please expand your disclosure to describe what you mean by the term “data-driven product design.”
|
|
The Company has added disclosure under the headings “Prospectus Summary—Overview—Our Company,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business—Overview—Our Company” to explain the term “data-driven product design.”
|
12.
|
Please expand your disclosure to describe “minimum MLR thresholds” and “must-carry pre-existing conditions requirements” here and on page 69 of the prospectus.
|
|
The Company has added disclosure under the headings “Prospectus Summary—Overview—Health Insurance Industry and Market Opportunity” and “Business—Overview—Health Insurance Industry and Market Opportunity” to describe “minimum MLR thresholds” and “must-carry pre-existing conditions requirements.”
|
13.
|
Please expand your disclosure to discuss the extent to which you currently offer products to insure individuals with pre-existing conditions and whether you plan to insure such individuals upon implementation of Healthcare Reform.
|
|
The Company has added disclosure under the headings “Prospectus Summary—Overview—Our Solutions” and “Business—Overview—Our Solutions” to discuss the extent to which it currently offers products to insure individuals with pre-existing conditions and note that it does not plan to expand such coverage upon implementation of Healthcare Reform.
|
14.
|
If you do not intend to offer products which cover pre-existing conditions, please revise the discussion relative to the anticipated total healthcare market to reflect your actual target market.
|
|
As described in the Company’s response to the Staff’s comment No. 13, the Company currently offers limited products to individuals with pre-existing conditions. Accordingly, the Company respectfully submits that no additional disclosure is required.
|
U.S. Securities and Exchange Commission
|
5
|
December 20, 2012
|
15.
|
Please revise your disclosure to clarify what you mean when you use the terms “due to their nature” when referring to your STM plans and hospital indemnity plans in the first bullet point under this section. Specifically, please explain why the nature of your STM plans enables you to provide an instant decision and why the nature of your hospital indemnity plans guarantee issuance to individuals under 65.
|
|
The Company has revised the disclosure under the headings “Prospectus Summary—Overview—Our Solutions” and “Business—Overview—Our Solutions” to clarify why instant decisions can be provided for STM plans and why the nature of hospital indemnity plans guarantee issuance to individuals under 65.
|
16.
|
Since you developed a web-based technology platform, please expand your discussion to explain the nature of and relationship of your call centers to such technology.
|
17.
|
Please expand your discussion to describe the nature of your relationship with MasterCard and when you began this relationship.
|
18.
|
Please expand your disclosure to indicate the purchase price for the acquisition.
|
|
The Company has added disclosure under the heading “Prospectus Summary—Our History and the Reorganization of Our Corporate Structure” to indicate the purchase price for the acquisition.
|
19.
|
Please revise the formatting of the information in the colored parts of your diagrams on pages 8 and 38 so that the text is legible.
|
20.
|
Please file the lease agreement pertaining to your principal executive offices as an exhibit.
|
U.S. Securities and Exchange Commission
|
6
|
December 20, 2012
|
21.
|
We note that your STM plans are currently classified as “short-term limited duration” plans under Healthcare Reform, and are therefore exempt from certain requirements. Please expand your disclosure to discuss these requirements.
|
22.
|
Please expand your disclosure to indicate the percentage of premium equivalents accounted for by Starr and United States Fire, respectively.
|
23.
|
Please expand your disclosure to quantify how much business you derive from the relationship with Med-Sense.
|
24.
|
We note that insurance carriers have altered the contractual relationships you have with them. Given that Starr Indemnity & Liability & Insurance Company and United States Fire accounted for an aggregate of 77.8% of your premium equivalents, please advise us whether either of these carriers has lowered the commission rates they pay you. If so, please revise your disclosure to include this information and the impact it has had on your business.
|
U.S. Securities and Exchange Commission
|
7
|
December 20, 2012
|
25.
|
We note that this risk factor covers the same topic as the one on page 24 entitled, “We may be unsuccessful in competing effectively against current and future competitors, which would impact our prospects as results of operations.” Please revise your disclosure to combine the two risk factors into a single risk factor.
|
|
The Company acknowledges the Staff’s comment and has combined the risk factors under the heading “Risk Factors—Risks Relating to Our Business and Industry—We face intense competition and compete with a broad range of market participants within the health insurance industry. If competition increases, our growth and profits may decline.”
|
26.
|
Please revise your disclosure to state whether you are currently in compliance with applicable insurance laws and regulations. If any adverse regulatory action has been taken against you, please describe the action including any liability imposed, additional department of insurance licensing requirements, or the revocation of licenses in a particular jurisdiction. Similarly, revise the risk factor entitled, “We are subject to privacy and data protection laws governing the transmission, security and privacy of health information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws” to discuss whether you have received notice of violation of these laws, the nature of the violation(s) and potential consequences.
|
|
The Company has revised the disclosure under the headings “Risk Factors—Risks Relating to Our Business and Industry—Compliance with the strict regulatory environment applicable to the health insurance industry and the specific products we sell is difficult and costly. If we fail to comply with the numerous laws and regulations that are applicable to our business, our business and results of operations would be harmed” and “Risk Factors—Risks Relating to Our Business and Industry—We are subject to privacy and data protection laws governing the transmission, security and privacy of health information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws” to state that the Company believes it is currently in compliance with applicable insurance laws and regulations and has not received any notice of violation of privacy and data protection laws governing the transmission, security and privacy of health information.
|
U.S. Securities and Exchange Commission
|
8
|
December 20, 2012
|
27.
|
Please expand your disclosure to identify your brand name(s).
|
28.
|
To the extent that you have received notice of claims against you by third-parties for violating their intellectual property rights, please discuss the situation and potential consequences in this risk factor discussion.
|
|
The Company has not received notice of any claims against it by third-parties for violating their intellectual property rights. Accordingly, the Company respectfully submits that no additional disclosure is required.
|
29.
|
To the extent that you have experienced problems attracting and retaining key members of your management team in the recent past, please revise your disclosure to describe these problems.
|
|
The Company has not experienced any problems attracting and retaining key members of its management team. The majority of the management team has worked together under the leadership of Mr. Kosloske, the Company’s Chairman, President, and Chief Executive Officer, for more than a decade. Accordingly, the Company respectfully submits that no additional disclosure is required.
|
30.
|
We note that your executive officers and directors will be subject to lock up agreements. Please file the agreements as exhibits to the registration statement.
|
31.
|
We note that you identified a material weakness where you did not have effective controls over the design and operation of the financial statement close process, which impacts most of your significant accounts included in the financial statements. Please expand your disclosure to clarify which accounts were impacted, how they were impacted and what affect this had on your financial statements. Also, please clarify when you
|
U.S. Securities and Exchange Commission
|
9
|
December 20, 2012
|
|
intend to take the steps described in the risk factor to address the material weakness and that the weakness will be ongoing until such steps are taken.
The Company has added disclosure under the heading “Risk Factors—Risks Relating to Our Business and Industry—We have identified a material weakness in our internal control over financial reporting that, if not corrected, could result in material misstatements in our financial statements” to clarify which accounts were impacted, how they were impacted and what affect this had on its financial statements, along with when it intends to take the steps described in the risk factor to address the material weakness and that the weakness will be ongoing until such steps are taken.
|
32.
|
We note that shares of your Class B common stock vote together with shares of your Class A common stock as a single class, subject to certain exceptions. Please include disclosure in your prospectus to describe these exceptions.
|
|
The Company has revised the disclosure under the heading “The Reorganization of Our Corporate Structure—Overview” to clarify that shares of its Class B common stock vote together with shares of its Class A common stock as a single class except as otherwise required by law.
|
33.
|
Please tell us why you believe the transaction with Albacore is a business combination and clarify how you intend to account for the operations of Albacore in the financial statements.
|
U.S. Securities and Exchange Commission
|
10
|
December 20, 2012
|
·
|
Trade names, trademarks, brand names, product names, web pages, websites or other proprietary technology of Amacore were not acquired or utilized by ICE;
|
·
|
Amacore customer lists were not acquired or utilized by ICE; and
|
·
|
Amacore’s automatic dialers were not acquired by ICE.
|
34.
|
We note that you may impose additional restrictions on exchange that you determine necessary or advisable so that Health Plan Intermediaries Holdings, LLC is not treated as a “publicly traded partnership” for U.S. federal income tax purposes. Please expand your disclosure to explain the significance of such designation and the effect on the registrant if Health Plan Intermediaries Holdings, LLC is considered a publicly traded partnership.
|
|
The Company has added disclosure under the heading “The Reorganization of Our Corporate Structure—Registration Rights Agreement—Exchange Agreement” to explain the significance of designation as a “publicly traded partnership” and the effect on the Company if Health Plan Intermediaries Holdings, LLC is considered a publicly traded partnership.
|
35.
|
Please revise your disclosure to provide the termination provisions of the tax receivable agreement. If these provisions have not been determined at this time, please provide the information once it is available.
|
|
The Company has added disclosure under the heading “The Reorganization of Our Corporate Structure—Registration Rights Agreement—Tax Receivable Agreement” to provide the termination provisions of the tax receivable agreement.
|
36.
|
To the extent material conflicts of interest exist with respect to the timing or use of benefits/tax savings, please expand the discussion in this section and include a risk factor addressing such conflicts.
|
|
In response to the Staff’s comment, the Company has added disclosure under the heading “Risk Factors—Risks Relating to our Business and Industry—We will be required to pay existing holders of Series B Membership Interests most of the tax benefits that we may receive as a result of the purchase of Series B Membership Interests with a portion of the net proceeds of this offering, future exchanges of Series B Membership Interests for our Class A common stock and payments made under the tax receivable agreement itself, and the amounts we pay could be substantial.”
|
U.S. Securities and Exchange Commission
|
11
|
December 20, 2012
|
37.
|
We note that you will have the right to delay, suspend or withdraw a registration statement under specified circumstances. Please expand your disclosure to describe these circumstances.
|
|
The Company has added disclosure under the heading “The Reorganization of Our Corporate Structure—Registration Rights Agreement—Conditions and Limitations” to describe the circumstances under which the Company will have the right to delay, suspend or withdraw a registration statement.
|
38.
|
We are deferring the review of your pro forma information until the amounts are disclosed. Please include explanatory notes to the pro forma financial information with a detailed explanation of your pro forma adjustments.
|
|
The Company will disclose pro forma information in a future amendment to the registration statement. The Company acknowledges the Staff’s comment and will include explanatory notes to the pro forma financial information with a detailed explanation of the pro forma adjustments at that time.
|
39.
|
You disclose that you have established your Insurance Academy in June 2012 to expand the number of call centers selling your products and that you anticipate that your Insurance Academy operations will closely resemble a franchise model. Please discuss the impact that this new activity is expected to have on your results from operations.
|
|
The Company has added disclosure under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Components of Our Statements of Operations—Noncontrolling Interest” to discuss the impact that the Insurance Academy is expected to have on its results from operations.
|
40.
|
We note that you believe that your available cash, cash flows expected to be generated from operations and net proceeds from this offering will be adequate to satisfy your current and planned operations in the “foreseeable future.” Please revise your disclosure to specify the amount of time that available cash can sustain operations.
|
|
The Company has added disclosure under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital
|
U.S. Securities and Exchange Commission
|
12
|
December 20, 2012
|
41.
|
Please revise your disclosure to clarify that the term loan agreement is with Sun Trust Bank.
|
|
The Company has revised the disclosure under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Our Indebtedness” to clarify that the term loan agreement is with Sun Trust Bank.
|
42.
|
We note that you intend to obtain Sun Trust Bank’s written consent in order to effectuate this offering. Please revise your disclosure to clarify whether you have taken any steps to obtain this consent, and if so, the status of the consent. If you have not taken any such steps, please disclose when you expect to obtain the bank’s consent.
|
|
The Company has added disclosure under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Our Indebtedness” to disclose when the Company expects to obtain Sun Trust Bank’s written consent for the offering.
|
43.
|
Please disclose the date your technology platform A.R.I.E.S. was placed in service. If the date is August 1, 2012, the date you entered into a software assignment agreement with BymSym, please disclose the platform you used prior to August 1, 2012 to sell products to your customers.
|
|
The Company has added disclosure under the heading “Business—Technology” to disclose the date the Company’s technology platform A.R.I.E.S. was placed in service and to disclose the platform the Company used prior to that time.
|
44.
|
To the extent practicable, please expand your disclosure in this section, in the subsection entitled “Our Company” and throughout your prospectus, as applicable, to quantify how your STM plans are more affordable than IMM plans. We note that in the subsection “Our Company” and throughout your prospectus, you state that your STM plans are up to half the cost of IMM plans.
|
|
The Company has added disclosure under the headings “Prospectus Summary—Our Competitive Strengths,” “Business—Our Competitive Strengths” and “Business—Our Products” to quantify how STM plans are more affordable than IMM plans.
|
U.S. Securities and Exchange Commission
|
13
|
December 20, 2012
|
45.
|
Please expand your discussion to include a comparison of the advantages and disadvantages between STM and IMM plans including:
|
|
•
|
Coverage for pre-existing conditions;
|
|
•
|
Prescription benefits;
|
|
•
|
Preventive care; and
|
|
•
|
Duration/renewability.
|
|
The Company has added disclosure under the heading “Business—Our Products” to include a comparison of the advantages and disadvantages between STM and IMM plans, including bullets 1-4 of the Staff’s comment.
|
46.
|
We note the increase in the number of STM plans in force between June 30, 2012 and June 30, 2011. Please expand your discussion to provide the retention rate for such plans from 2011 to 2012.
|
|
The Company has added disclosure under the headings “Prospectus Summary—Overview—Our Company,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business—Overview—Our Company” to provide the retention rate for STM plans in force from 2011 to 2012.
|
47.
|
Please revise the information for Mr. Raeckers and Ms. O’Drobinak to include their business experience for at least the past five years.
|
|
The Company has revised the disclosure under the heading “Management—Executive Officers and Directors” to include their business experience for the past five years.
|
48.
|
Please tell us whether Mr. Kosloske will continue to receive revenues from certain prescription contracts and commissions on yearly revenues. We may have additional comments.
|
|
The Company has added disclosure under the heading “Relationships and Related Transactions—Employment Contracts” to clarify that Mr. Kosloske has not received revenues from certain prescription contracts and commissions on yearly revenues since October 2011, and he will not receive such revenues under any current or proposed employment contract.
|
U.S. Securities and Exchange Commission
|
14
|
December 20, 2012
|
49.
|
Please revise your disclosure to describe the unreimbursed expenses that were paid by Mr. Kosloske on the company’s behalf.
|
50.
|
Please remove the amounts and references to premium equivalents from your financial statements or tell us why presenting a non-GAAP financial measure on the face of the statements of operations is appropriate.
|
|
·
|
The amount presented may not be termed or described as “revenue;” and
|
|
·
|
The amount must be presented in a separate column from actual revenue and excluded from the summation of net income or net loss.
|
U.S. Securities and Exchange Commission
|
15
|
December 20, 2012
|
51.
|
Please tell us your consideration of whether the payment received from members referred to as “premium equivalents” represent a multiple element arrangement accounted for under ASC 605-25. If you do not believe it is a multiple element arrangement, please tell us why. Clearly disclose the accounting treatment for each deliverable. Tell us the amounts earned from each of your major revenue sources such as the sale of hospital indemnity policies, commissions from the sale of STM plans, the various ancillary plans and all other major revenue sources for all periods presented.
|
52.
|
Disclose in the filing the process you follow to report and pay amounts due to insurance carriers and discount benefit vendors. Also disclose the reporting time lag.
|
|
The Company has added disclosure under the heading “Organization, Basis of Presentation and Summary of Significant Accounting Policies—Revenue Recognition” to disclose the process the Company follows to report and pay amounts due to insurance carriers and discount benefit vendors including the reporting time lag.
|
53.
|
Please elaborate on your statement that revenue is earned upon the acceptance of the policy. Refer to SAB Topic 13. Disclose if the acceptance date coincides with the effective date of the policy and with the date you recognize commission and fee
|
U.S. Securities and Exchange Commission
|
16
|
December 20, 2012
|
54.
|
Revise your disclosure to explain the nature of the risk premium included in members’ payments and clarify your accounting for the risk premium.
|
55.
|
You disclose that you recognize revenues net of amounts paid to contracted insurance carrier companies as the agent in such transactions. Please tell us and revise your disclosures to clarify the factors you considered in concluding that revenues should be reported on a net basis. Refer to ASC 605-45-45.
|
U.S. Securities and Exchange Commission
|
17
|
December 20, 2012
|
U.S. Securities and Exchange Commission
|
18
|
December 20, 2012
|
INDIVIDUAL SHORT-TERM MEDICAL WRITERS, 2011
|
Life | |||
Health |
New Writer in 2011
|
||
P&C |
NAIC Code | Entity Name | State Domiciled |
AM Best Rating |
2011 Premiums Earned ($000) | Incurred Claims Amount ($000) | Change in Contract Reserves ($000) | Loss Ratio (%) | Number of Policies or Certificates as of Dec. 31 (Actual) | Number of Covered Lives as of Dec. 31 (Actual) | Member Months (Actual) | 2010 Premiums Earned ($000) | $ Change 2011 vs 2010 | ||||||||||
69477
|
Time Insurance Co.
|
WI
|
A-
|
23,918
|
13,072
|
20
|
54.74
|
9,668
|
13,394
|
203,835
|
30,498
|
-22
|
%
|
|||||||||
70670
|
HlthCare Svc Corp. a Mutual
|
IL
|
A+
|
15,413
|
10,160
|
0
|
65.92
|
9,036
|
12,632
|
167,388
|
12,507
|
23
|
%
|
|||||||||
73288
|
Humana Insurance Co (WI)
|
WI
|
A-
|
11,295
|
6,192
|
0
|
54.82
|
6,044
|
8,915
|
99,975
|
6,396
|
77
|
%
|
|||||||||
65080
|
John Alden Life Insurance Co.
|
WI
|
A-
|
4,518
|
2,663
|
35
|
59.72
|
1,588
|
2,328
|
34,414
|
5,725
|
-21
|
%
|
|||||||||
66141
|
Health Net Life Insurance Co.
|
CA
|
B++
|
3,615
|
2,170
|
0
|
60.02
|
2,151
|
2,980
|
42,405
|
0
|
|||||||||||
97985
|
LifeMap Assurance Co.
|
OR
|
A-
|
3,525
|
2,477
|
0
|
70.27
|
3,461
|
5,223
|
72,503
|
2,342
|
51
|
%
|
|||||||||
62286
|
Golden Rule Insurance Co.
|
IN
|
A
|
3,495
|
3,131
|
0
|
89.56
|
2,017
|
3,248
|
45,541
|
3,425
|
2
|
%
|
|||||||||
55026
|
BCBSM Inc.
|
MN
|
A-
|
2,398
|
1,332
|
0
|
55.54
|
1,728
|
2,666
|
30,780
|
2,983
|
-20
|
%
|
|||||||||
55204
|
HealthNow New York Inc.
|
NY
|
2,222
|
3,243
|
0
|
145.98
|
1,185
|
1,342
|
17,432
|
0
|
||||||||||||
54801
|
BC&BS of Georgia Inc.
|
GA
|
A
|
1,755
|
890
|
0
|
50.68
|
790
|
1,098
|
16,859
|
1,975
|
-11
|
%
|
|||||||||
55433
|
Blue Cross & Blue Shield of AL
|
AL
|
1,721
|
1,857
|
0
|
107.89
|
1,714
|
1,714
|
19,442
|
1,180
|
46
|
%
|
||||||||||
10345
|
Community Insurance Co.
|
OH
|
A
|
1,660
|
1,090
|
0
|
65.68
|
603
|
793
|
14,382
|
0
|
|||||||||||
62825
|
Anthem Blue Cross L&H Ins Co.
|
CA
|
A
|
1,578
|
1,031
|
0
|
65.33
|
524
|
747
|
13,850
|
1,707
|
-8
|
%
|
|||||||||
54518
|
BlueCross BlueShield of TN Inc
|
TN
|
1,434
|
1,641
|
0
|
114.45
|
1,629
|
2,339
|
29,913
|
1,440
|
0
|
%
|
||||||||||
28207
|
Anthem Insurance Companies Inc
|
IN
|
A
|
1,194
|
1,745
|
0
|
146.16
|
2
|
6
|
73
|
3,420
|
-65
|
%
|
|||||||||
95120
|
Anthem Health Plans of KY Inc.
|
KY
|
A
|
1,128
|
717
|
0
|
63.57
|
552
|
780
|
12,323
|
1,265
|
-11
|
%
|
|||||||||
88848
|
Wellmark Inc.
|
IA
|
A
|
1,016
|
691
|
0
|
68.01
|
762
|
1,101
|
14,122
|
1,212
|
-16
|
%
|
|||||||||
71835
|
Anthem Health Plans of VA Inc.
|
VA
|
A
|
936
|
417
|
0
|
44.59
|
508
|
669
|
14,014
|
1,181
|
-21
|
%
|
|||||||||
77950
|
Health Alliance Med Plans Inc.
|
IL
|
B++
|
716
|
732
|
0
|
102.24
|
509
|
755
|
5,490
|
761
|
-6
|
%
|
|||||||||
60095
|
Blue Cross of Idaho Health Svc
|
ID
|
700
|
269
|
0
|
38.46
|
620
|
906
|
7,852
|
535
|
31
|
%
|
||||||||||
95885
|
Humana Health Plan Inc.
|
KY
|
A-
|
691
|
245
|
0
|
35.40
|
517
|
726
|
8,287
|
429
|
61
|
%
|
|||||||||
47171
|
BC&BS of Kansas City
|
MO
|
674
|
462
|
0
|
68.49
|
482
|
626
|
8,159
|
690
|
-2
|
%
|
||||||||||
92711
|
HCC Life Insurance Co.
|
IN
|
A+
|
657
|
230
|
0
|
35.03
|
1,930
|
1,930
|
23,160
|
193
|
240
|
%
|
|||||||||
80799
|
Celtic Insurance Co.
|
IL
|
B++
|
632
|
542
|
0
|
85.81
|
1,310
|
1,843
|
24,103
|
150
|
322
|
%
|
|||||||||
63245
|
SelectHealth Benefit Assr Co.
|
UT
|
589
|
184
|
0
|
31.21
|
380
|
798
|
10,303
|
0
|
||||||||||||
29076
|
Medical Mutual of Ohio
|
OH
|
582
|
150
|
0
|
25.75
|
467
|
710
|
5,251
|
0
|
||||||||||||
67628
|
Pekin Life Insurance Co.
|
IL
|
A-
|
580
|
497
|
0
|
85.75
|
439
|
649
|
7,104
|
779
|
-26
|
%
|
|||||||||
11994
|
UPMC Health Network Inc.
|
PA
|
B++
|
531
|
1,380
|
0
|
259.88
|
0
|
0
|
3,372
|
0
|
|||||||||||
11018
|
UPMC Health Benefits Inc.
|
PA
|
B++
|
524
|
651
|
0
|
124.32
|
746
|
746
|
4,125
|
0
|
|||||||||||
53686
|
Blue Cross & Blue Shield of MT
|
MT
|
523
|
169
|
0
|
32.24
|
322
|
439
|
6,218
|
461
|
13
|
%
|
||||||||||
60836
|
American Republic Insurance Co
|
IA
|
A-
|
459
|
194
|
0
|
42.28
|
290
|
398
|
4,729
|
158
|
190
|
%
|
|||||||||
12459
|
Medica Insurance Co.
|
MN
|
423
|
428
|
0
|
101.23
|
420
|
517
|
7,885
|
304
|
39
|
%
|
||||||||||
95800
|
Health Net Hlth Plan of OR Inc
|
OR
|
B++
|
359
|
169
|
0
|
47.20
|
157
|
192
|
3,566
|
126
|
186
|
%
|
|||||||||
71870
|
Fidelity Security Life Ins Co.
|
MO
|
A-
|
339
|
266
|
0
|
78.36
|
195
|
195
|
8,106
|
597
|
-43
|
%
|
|||||||||
60128
|
Wellmark of South Dakota Inc.
|
SD
|
A
|
336
|
338
|
0
|
100.56
|
269
|
371
|
4,947
|
439
|
-23
|
%
|
|||||||||
41203
|
Capital Advantage Insurance Co
|
PA
|
265
|
350
|
-36
|
118.68
|
0
|
0
|
0
|
459
|
-42
|
%
|
||||||||||
12208
|
Priority Health Insurance Co.
|
MI
|
252
|
86
|
0
|
34.15
|
0
|
386
|
3,126
|
0
|
||||||||||||
70211
|
Reassure America Life Ins Co.
|
IN
|
A+
|
231
|
108
|
-71
|
15.98
|
3,419
|
4,172
|
50,064
|
254
|
-9
|
%
|
|||||||||
70629
|
World Insurance Co.
|
NE
|
A-
|
195
|
44
|
0
|
22.67
|
71
|
98
|
1,664
|
218
|
-11
|
%
|
|||||||||
11011
|
Rocky Mtn Hosp & Med Svc Inc.
|
CO
|
A
|
145
|
52
|
0
|
35.60
|
88
|
127
|
1,817
|
182
|
-20
|
%
|
|||||||||
19720
|
American Alternative Ins Corp.
|
DE
|
A+
|
87
|
25
|
0
|
28.07
|
5
|
5
|
1,016
|
140
|
-38
|
%
|
|||||||||
53759
|
Anthem Health Plans of NH Inc.
|
NH
|
A
|
71
|
42
|
0
|
58.48
|
16
|
19
|
511
|
0
|
|||||||||||
70729
|
BC&BS of Kansas Inc.
|
KS
|
A
|
65
|
30
|
0
|
46.15
|
41
|
66
|
794
|
67
|
-3
|
%
|
|||||||||
54720
|
Capital Blue Cross
|
PA
|
39
|
42
|
5
|
118.86
|
161
|
226
|
892
|
0
|
||||||||||||
54976
|
PacificSource Health Plans
|
OR
|
B++
|
39
|
104
|
0
|
265.92
|
0
|
0
|
530
|
912
|
-96
|
%
|
|||||||||
95642
|
Humana Hlth Benefit Plan of LA
|
LA
|
A-
|
4
|
21
|
0
|
582.21
|
0
|
0
|
54
|
144
|
-97
|
%
|
|||||||||
80314
|
UNICARE L&H Insurance Co.
|
IN
|
A-
|
0
|
0
|
0
|
(8,725.00
|
)
|
0
|
0
|
2
|
37
|
-100
|
%
|
||||||||
81043
|
Bankers Life Insurance Co.
|
FL
|
B
|
0
|
1
|
0
|
-
|
0
|
0
|
0
|
1
|
-100
|
%
|
|||||||||
64211
|
Guarantee Trust Life Ins Co.
|
IL
|
B+
|
0
|
1
|
0
|
-
|
0
|
0
|
0
|
0
|
|||||||||||
65781
|
Madison National Life Ins Co.
|
WI
|
A-
|
0
|
-44
|
0
|
26,700.60
|
0
|
0
|
0
|
227
|
-100
|
%
|
|||||||||
93,528
|
62,284
|
(46
|
)
|
66.54
|
56,816
|
78,875
|
1,052,378
|
85,519
|
9
|
%
|
||||||||||||
60305 American Community Mutl Ins Co
|
700
|
-100
|
%
|
|||||||||||||||||||
19275 American Family Mutual Ins Co.
|
WI
|
A
|
184
|
-100
|
%
|
|||||||||||||||||
33162 Bankers Insurance Co.
|
FL
|
B+
|
88
|
-100
|
%
|
|||||||||||||||||
70700 UNICARE Hlth Ins Co. of the MW
|
IL
|
A-
|
24
|
-100
|
%
|
|||||||||||||||||
10386 American Family Insurance Co.
|
OH
|
A
|
5
|
-100
|
%
|
|||||||||||||||||
87726 MetLife Insurance Co. of CT
|
CT
|
A+
|
0
|
|||||||||||||||||||
86,521
|
8
|
%
|